Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Adv Exp Med Biol ; 1447: 117-129, 2024.
Article in English | MEDLINE | ID: mdl-38724789

ABSTRACT

With recent advances in topical therapies for atopic dermatitis (AD), steroid-sparing options like calcineurin inhibitors, Janus kinase (JAK) inhibitors, and phosphodiesterase-4 (PDE-4) inhibitors are becoming mainstays in therapy, underscoring the importance of careful selection and usage of topical corticosteroids (TCSs) to minimize side effects. Alongside the necessity of emollient use, these steroid-sparing alternatives offer rapid itch relief and efficacy in improving disease severity. While TCSs still hold a prominent role in AD management, promising novel topical treatments like tapinarof and live biotherapeutics to modulate the skin microbiome are also discussed. Overall, the recent addition of novel topical therapies offers diverse options for AD management and underscores the importance of topical treatments in the management of AD.


Subject(s)
Dermatitis, Atopic , Humans , Dermatitis, Atopic/drug therapy , Dermatitis, Atopic/microbiology , Administration, Topical , Adrenal Cortex Hormones/therapeutic use , Adrenal Cortex Hormones/administration & dosage , Phosphodiesterase 4 Inhibitors/therapeutic use , Administration, Cutaneous , Skin/drug effects , Skin/microbiology , Skin/pathology , Calcineurin Inhibitors/therapeutic use , Calcineurin Inhibitors/administration & dosage , Dermatologic Agents/therapeutic use , Dermatologic Agents/administration & dosage , Dermatologic Agents/adverse effects
2.
Clin Exp Ophthalmol ; 47(1): 7-14, 2019 01.
Article in English | MEDLINE | ID: mdl-29920898

ABSTRACT

IMPORTANCE: Diagnosis codes are inadequate for accurately identifying herpes zoster (HZ) ophthalmicus (HZO). There is significant lack of population-based studies on HZO due to the high expense of manual review of medical records. BACKGROUND: To assess whether HZO can be identified from the clinical notes using natural language processing (NLP). To investigate the epidemiology of HZO among HZ population based on the developed approach. DESIGN: A retrospective cohort analysis. PARTICIPANTS: A total of 49 914 southern California residents aged over 18 years, who had a new diagnosis of HZ. METHODS: An NLP-based algorithm was developed and validated with the manually curated validation data set (n = 461). The algorithm was applied on over 1 million clinical notes associated with the study population. HZO versus non-HZO cases were compared by age, sex, race and co-morbidities. MAIN OUTCOME MEASURES: We measured the accuracy of NLP algorithm. RESULTS: NLP algorithm achieved 95.6% sensitivity and 99.3% specificity. Compared to the diagnosis codes, NLP identified significant more HZO cases among HZ population (13.9% vs. 1.7%). Compared to the non-HZO group, the HZO group was older, had more males, had more Whites and had more outpatient visits. CONCLUSIONS AND RELEVANCE: We developed and validated an automatic method to identify HZO cases with high accuracy. As one of the largest studies on HZO, our finding emphasizes the importance of preventing HZ in the elderly population. This method can be a valuable tool to support population-based studies and clinical care of HZO in the era of big data.


Subject(s)
Algorithms , Eye Infections, Viral/diagnosis , Herpes Zoster Ophthalmicus/diagnosis , Herpesvirus 3, Human , Natural Language Processing , Population Surveillance/methods , Adolescent , Adult , Aged , Aged, 80 and over , Eye Infections, Viral/virology , Female , Follow-Up Studies , Herpes Zoster Ophthalmicus/virology , Humans , Male , Middle Aged , ROC Curve , Reproducibility of Results , Retrospective Studies , Young Adult
3.
Adv Exp Med Biol ; 1027: 105-120, 2017.
Article in English | MEDLINE | ID: mdl-29063435

ABSTRACT

Atopic dermatitis frequently requires the use of over-the-counter and prescription medications for effective management. Emollients and topical corticosteroids are effective for most patients and are the most commonly utilized agents by experienced dermatologists. Antihistamines, antibiotics, and calcineurin inhibitors may also prove helpful in the correct clinical scenarios. Severe atopic dermatitis, however, can be difficult to manage and not infrequently require substantial immunomodulatory medications. Targeted molecular therapies, such as dupilumab, are promising, emerging atopic dermatitis therapies. The medication pearls reviewed in this chapter will assist providers in managing atopic dermatitis patients.


Subject(s)
Dermatitis, Atopic/drug therapy , Adrenal Cortex Hormones/administration & dosage , Anti-Bacterial Agents/therapeutic use , Calcineurin Inhibitors/administration & dosage , Histamine Antagonists/therapeutic use , Humans , Immunologic Factors/therapeutic use
4.
Vaccine ; 35(48 Pt B): 6672-6675, 2017 12 04.
Article in English | MEDLINE | ID: mdl-29079102

ABSTRACT

PURPOSE: Estimate incidence of autoimmune conditions in a population who received HPV4 vaccine and a comparison unvaccinated population. Electronic health record (EHR) data may contain inaccurate or incomplete coding, while manual chart review of all cases may not be feasible. We propose a method to estimate incidence using EHR data and case review for a sample. METHODS: Suspected incident cases were identified using ICD-9 codes, laboratory results and medications related to the condition. A random sample of charts was reviewed to confirm the diagnosis and determine disease onset date. Multiple imputation, using a Monte Carlo model including age and disease indicators was used to impute case status of non-reviewed cases. Incidence rate was calculated in each imputed dataset, with median and percentiles giving a distribution for the estimated incidence rate. Sensitivity analyses compared modeled results to results without imputation and results where imputation was applied to the subset of cases identified using specific ICD-9 codes. RESULTS: The model accounted for differential case confirmation rates by age and method of case identification, identifying a potential safety signal that was missed relying on EHR data alone. CONCLUSIONS: This method may be useful for computing incidence when full case review is not feasible.


Subject(s)
Autoimmune Diseases/epidemiology , Data Accuracy , Incidence , Research Design , Adolescent , Adult , Algorithms , Child , Electronic Health Records , Female , Humans , Male , Morbidity , Vaccination/statistics & numerical data , Young Adult
5.
Adv Radiat Oncol ; 2(1): 6-11, 2017.
Article in English | MEDLINE | ID: mdl-28740910

ABSTRACT

PURPOSE: Radiation therapy plays an essential role in the treatment of locally advanced lung cancer, but it inevitably leads to incidental and unnecessary dose to critical organs, including the lung, heart, and esophagus. Numerous radiation dose-volumetric parameters have been associated with increased risk of morbidity and mortality. The purpose of the present study is to quantify differences in normal tissue radiation exposure with intensity modulated radiation therapy (IMRT) compared with 3-dimensional conformal radiation therapy (3D-CRT). METHODS AND MATERIALS: Twenty-four consecutive patients with locally advanced lung cancer undergoing definitive IMRT were enrolled on a phase 1 protocol. For each patient, an optimized 3D-CRT plan was also designed. Plans were normalized in terms of planning target coverage with a standard dose of 60 Gy in 2-Gy fractions with a subset of patients also receiving elective nodal irradiation to a dose of 44 Gy in 2-Gy fractions. Normal tissue dosimetric comparisons were made for the lung, heart, and esophagus. RESULTS: IMRT decreased incidental dose to the lungs, heart, and esophagus. For lung, both V20 Gy (21.5% vs 26.5%, P < .01) and mean lung dose (11.9 Gy vs 14.9 Gy, P < .01) were improved with IMRT without a corresponding increase in V5 Gy (P = .76). For heart, there was improvement in V5 (28.9% vs 33.7%, P < .01) but no difference in V30 Gy (9.8% vs 15.9%. P = .10). For esophagus, all dosimetric endpoints were improved (V20 Gy, V45 Gy, V60 Gy, mean dose). For example, V60 was 6.5% with IMRT compared with 21% with 3D-CRT (P < .01). CONCLUSIONS: IMRT significantly decreased unnecessary dose to critical organs with equivalent coverage of planning target volumes. IMRT may therefore improve the tolerability of therapy.

SELECTION OF CITATIONS
SEARCH DETAIL
...